Testmiljö
Observera att detta är en testmiljö för utveckling som inte ska användas som underlag för klinisk bedömning. Besök Janusmed här: https://janusmed.se

5/2/2024

Janusmed fosterpåverkan

Janusmed fosterpåverkan – Pylera

Janusmed fosterpåverkan tillhandahåller bedömningar av eventuella risker för fostret, när en gravid kvinna använder olika läkemedel. Observera att texterna är generella, och att en bedömning måste göras i varje enskilt fall. Om du inte är medicinskt utbildad, läs först vår information för patienter och allmänhet.

För att komma till startsidan för Janusmed fosterpåverkan och för att göra sökningar klicka här.

Tillbaka till index
2 2
2 2

Metronidazol Testmiljö

Metronidazol

Klass : 2

Visa all info

Skriv ut

Kontakta oss

  1. Briggs G, Freeman RK, Towers CV, Forinash AB. Drugs in pregnancy and lactation: A reference guide to fetal and neonatal risk. 11th ed; 2017.

  2. Cantu JM, Garcia-Cruz D. Midline facial defect as a teratogenic effect of metronidazole. Birth Defects Orig Artic Ser 1982;18:85-8.

  3. Greenberg F. Possible metronidazole teratogenicity and clefting. Am J Med Genet. 1985;22(4):825.

  4. Berget A, Weber T. [Metronidazole and pregnancy]. Ugeskr Laeger 1972;134:2085-9.

  5. Piper JM, Mitchel EF, Ray WA. Prenatal use of metronidazole and birth defects: no association. Obstet Gynecol 1993;82:348-52.

  6. Burtin P, Taddio A, Ariburnu O et al. Safety of metronidazole in pregnancy: a meta-analysis. Am J Obstet Gynecol 1995;172:525-9.

  7. Caro-Patón T, Carvajal A, Martin de Diego I, Martin-Arias LH, Alvarez Requejo A, Rodríguez Pinilla E. Is metronidazole teratogenic? A meta-analysis. Br J Clin Pharmacol. 1997;44(2):179-82.

  8. Czeizel AE, Rockenbauer M. A population based case-control teratologic study of oral metronidazole treatment during pregnancy. Br J Obstet Gynaecol 1998;105:322-7.

  9. Diav-Citrin O, Shechtman S, Gotteiner T, Arnon J, Ornoy A. Pregnancy outcome after gestational exposure to metronidazole: A prospective controlled cohort study. Teratology 2001;63:186-92.

  1. Briggs G, Freeman RK, Towers CV, Forinash AB. Drugs in pregnancy and lactation: A reference guide to fetal and neonatal risk. 11th ed; 2017.
  2. Cantu JM, Garcia-Cruz D. Midline facial defect as a teratogenic effect of metronidazole. Birth Defects Orig Artic Ser 1982;18:85-8.
  3. Greenberg F. Possible metronidazole teratogenicity and clefting. Am J Med Genet. 1985;22(4):825.
  4. Berget A, Weber T. [Metronidazole and pregnancy]. Ugeskr Laeger 1972;134:2085-9.
  5. Piper JM, Mitchel EF, Ray WA. Prenatal use of metronidazole and birth defects: no association. Obstet Gynecol 1993;82:348-52.
  6. Burtin P, Taddio A, Ariburnu O et al. Safety of metronidazole in pregnancy: a meta-analysis. Am J Obstet Gynecol 1995;172:525-9.
  7. Caro-Patón T, Carvajal A, Martin de Diego I, Martin-Arias LH, Alvarez Requejo A, Rodríguez Pinilla E. Is metronidazole teratogenic? A meta-analysis. Br J Clin Pharmacol. 1997;44(2):179-82.
  8. Czeizel AE, Rockenbauer M. A population based case-control teratologic study of oral metronidazole treatment during pregnancy. Br J Obstet Gynaecol 1998;105:322-7.
  9. Diav-Citrin O, Shechtman S, Gotteiner T, Arnon J, Ornoy A. Pregnancy outcome after gestational exposure to metronidazole: A prospective controlled cohort study. Teratology 2001;63:186-92.
2 2
2 2

Tetracyklin Testmiljö

Tetracyklin

Klass : 2

Visa all info

Skriv ut

Kontakta oss

  1. Cross R, Ling C, Day NP, McGready R, Paris DH. Revisiting doxycycline in pregnancy and early childhood--time to rebuild its reputation?. Expert Opin Drug Saf. 2016;15:367-82.

  2. Czeizel AE, Rockenbauer M. A population-based case-control teratologic study of oral oxytetracycline treatment during pregnancy. Eur J Obstet Gynecol Reprod Biol 2000;88:27-33.

  3. Czeizel AE, Rockenbauer M. Teratogenic study of doxycycline. Obstet Gynecol 1997;89:524-8.

  4. Damkier P, Brønniche LMS, Korch-Frandsen JFB, Broe A. In utero exposure to antibiotics and risk of congenital malformations: a population-based study. Am J Obstet Gynecol. 2019;221(6):648e1-648e15.

  1. Cross R, Ling C, Day NP, McGready R, Paris DH. Revisiting doxycycline in pregnancy and early childhood--time to rebuild its reputation?. Expert Opin Drug Saf. 2016;15:367-82.
  2. Czeizel AE, Rockenbauer M. A population-based case-control teratologic study of oral oxytetracycline treatment during pregnancy. Eur J Obstet Gynecol Reprod Biol 2000;88:27-33.
  3. Czeizel AE, Rockenbauer M. Teratogenic study of doxycycline. Obstet Gynecol 1997;89:524-8.
  4. Damkier P, Brønniche LMS, Korch-Frandsen JFB, Broe A. In utero exposure to antibiotics and risk of congenital malformations: a population-based study. Am J Obstet Gynecol. 2019;221(6):648e1-648e15.
2 2
2 2

Vismutsubcitrat Testmiljö

Vismutsubcitrat

Klass : 2

Visa all info

Skriv ut

Kontakta oss

  1. Lambert JR. Pharmacology of bismuth-containing compounds. Rev Infect Dis. 1991;13 Suppl 8:S691-5.

  2. Boertz J, Hartmann LM, Sulkowski M, Hippler J, Mosel F, Diaz-Bone RA et al. Determination of trimethylbismuth in the human body after ingestion of colloidal bismuth subcitrate. Drug Metab Dispos. 2009;37(2):352-8.

  3. Çelebi-Tayfur A, Yaradılmış RM, Ulus F, Çaltık-Yılmaz A, Özayar E, Koşar B et al. Bismuth intoxication resulting in acute kidney injury in a pregnant adolescent girl. Turk J Pediatr. 2019;61(2):292-296.

  1. Lambert JR. Pharmacology of bismuth-containing compounds. Rev Infect Dis. 1991;13 Suppl 8:S691-5.
  2. Boertz J, Hartmann LM, Sulkowski M, Hippler J, Mosel F, Diaz-Bone RA et al. Determination of trimethylbismuth in the human body after ingestion of colloidal bismuth subcitrate. Drug Metab Dispos. 2009;37(2):352-8.
  3. Çelebi-Tayfur A, Yaradılmış RM, Ulus F, Çaltık-Yılmaz A, Özayar E, Koşar B et al. Bismuth intoxication resulting in acute kidney injury in a pregnant adolescent girl. Turk J Pediatr. 2019;61(2):292-296.